Celgene Drops Crohn’s Disease Drug

Celgene abandoned development of its Crohn’s disease drug Revolve (mongersen) after disappointing results from a Phase III clinical trial.

The drug failed to pass muster in an interim futility analysis, the company said.

Celgene said it will continue development of other drugs for Crohn’s.